About Knowledge and Technology Alliance for Hepatitis C Management

Hepatitis C virus (HCV) has long been a detrimental drastic health problem in Egypt. Till recently, pegylated interferon represented the cornerstone line of treatment with suboptimal response and numerous significant side effects.

New era for management of HCV started with the appearance of direct acting antivirals. Combined sofosbuvir (NS5b inhibitor) and Ravidasvir (NS5a inhibitor) provided excellent results in managing HCV in adults and elderly, even in difficult scenarios such as treatment experienced and cirrhotic patients.

Early treatment of patients led to fibrosis regression and prevention of cirrhosis. However, treatment was recommended to start by age of 18 and was prohibited for younger patients.

Hereby, we decided to enroll a multicenteric clinical trial that focuses on adolescents (12-18 years old) who suffer from chronic HCV to manage them and study the pharmacokinetics of the drugs for such age group as well as recording the sustained virologic response (SVR) rates.